Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic lymphocytic leukemia
Biotech
Allogene abandons leukemia CAR-T plans after Breyanzi approval
Allogene has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from the likes of Bristol Myers Squibb.
James Waldron
Nov 14, 2024 5:59am
Tough markets take a double hit on Vincerx with layoffs
Jun 7, 2022 10:00am
TG's leukemia combo clears phase 3, aims for 2020 filing
May 5, 2020 9:55am
Merck inks $2.7B ArQule deal, teeing up cancer race with Lilly
Dec 9, 2019 10:25am
Lilly plots 'ambitious' cancer program after sharing early data
Dec 8, 2019 4:30pm
TG Therapeutics’ umbralisib shrinks tumors in 52% of MZL patients
Apr 1, 2019 8:30am
